Combination of Serine Protease Inhibitor FUT-175 and Thromboxane Synthetase Inhibitor OKY-046 Decreases Cerebral Vasospasm in Patients with Subarachnoid Hemorrhage

Makio KAMINO, Masahiro YONEKURA*, Masanari ONIZUKA, Akio YASUNAGA, and Shobu SHIBATA

Abstract

The preventive effect of the serine protease inhibitor FUT-175 (nafamostat mesilate), a potent inhibitor of the complement system, against vasospasm was evaluated in 34 high risk patients with thick and diffuse subarachnoid hemorrhage (SAH) demonstrated by computed tomography corresponding to Fisher group 3. All patients underwent surgery within 96 hours following SAH and received the thromboxane A2 synthetase inhibitor, OKY-046, as part of standard care. FUT-175 (40–160 mg/day) was administered during the initial 4 days following surgery. 455 patients treated without FUT-175 in the Nagasaki SAH Data Bank (non-FUT group) formed the control group. FUT-175 significantly decreased the incidence of symptomatic vasospasm in patients with severe neurological grade (Hunt and Hess grade 3, p < 0.02; Hunt and Hess grade 4, p < 0.02). The incidence of favorable outcome was 76.5% in the FUT group and 60.4% in the non-FUT group, but not statistically different. However, when patients of Hunt and Hess grade 5 were excluded, the FUT group had a significantly improved outcome (p < 0.05). This study suggests that FUT-175 has an additive effect to OKY-046 in preventing vasospasm in high risk patients with severe SAH.

Key words: cerebral aneurysm, serine protease inhibitor, subarachnoid hemorrhage, thromboxane A2 synthetase inhibitor, vasospasm

Introduction

Delayed ischemic neurological deficit (DIND) due to chronic cerebral vasospasm continues to be the major cause of poor clinical outcome in patients with subarachnoid hemorrhage (SAH). Many therapeutic agents are in use to prevent or reduce vasospasm, but no definitive treatment has been identified. Recent experimental and clinical studies suggest that the inflammatory process is important in the pathogenesis of vasospasm. Histological examination has demonstrated infiltration of neutrophils, lymphocytes, plasma cells, and macrophages into spastic arterial walls in humans and experimental animals as well as deposition of immunoglobulin G and the complement component C3. Furthermore, within 48 hours of SAH, significant activation of the complement components C3 and C4 occurred in the cerebrospinal fluid (CSF) space of patients who later developed DIND. The elevated levels of these complement components in the early post-SAH period fell rapidly within a few days. Also, a high serum concentration of immunocomplexes precedes the onset of vasospasm. These observations support the hypothesis that the inflammatory process, particularly activation of the complement system, may trigger vasospasm, and therefore treatment with FUT-175 (nafamostat mesilate), an inhibitor of the complement system, in the very early post-SAH period will prevent vasospasm. The amount of clot in the basal cistern is a risk factor for chronic vasospasm and the incidence of symptomatic vasospasm is greater than 50% in patients with thick SAH on computed tomography (CT). This study evaluated the use of FUT-175 in addi-
tion to a thromboxane A₂ (TXA₂) synthetase inhibitor OKY-046 (sodium ozagrel) for the treatment of high risk patients with thick and diffuse SAH on CT.

Materials and Methods

This study included 34 patients with diffuse and thick clot in the subarachnoid space (Fisher group 3) who underwent clipping of the aneurysm within 96 hours of first onset of symptoms between 1990 and 1995 (FUT group). Patients with intracerebral or intraventricular clot as well as diffuse and thick clot in the subarachnoid space were also included. Informed consent was obtained from the patients or guardians. Continuous intravenous infusion of OKY-046 (80 mg/day) was carried out from the day following surgery to day 14 of SAH. FUT-175 (40–160 mg/day, divided into 2–4 doses) was administered intravenously for the initial 4 days following surgery. The rate of infusion was approximately 20 mg/60 min.

The aim of the present study was to evaluate the effect of additional use of FUT-175 to OKY-046 for the prevention of vasospasm. Therefore, 455 patients classified in Fisher group 3, and who underwent surgery within 96 hours following SAH, followed by treatment with OKY-046 from the Nagasaki SAH Data Bank formed the control group (non-FUT group). Patients who had new neurological deficits immediately after the operation were excluded. Other treatments for vasospasm such as hypertensive hypervolemic therapy, low molecular weight dextran, mannitol, and glycerol were allowed. Calcium antagonist to control blood pressure was also allowed. However, aggressive removal of subarachnoid clots during surgery was not usually employed in either the FUT group or the non-FUT group.

Comparison of the characteristics of the patients, including age, sex, neurological severity of SAH, location of aneurysm, and timing of surgery between the two groups found no statistical difference (Table 1). Cisternal drainage was placed in all patients in the FUT group. CSF drainage was not used in 40 patients and only ventricular drainage in 21 patients in the non-FUT group. The cisternal drainage and/or the spinal drainage was placed in the remaining 394 cases in the non-FUT group.

The diagnosis of symptomatic vasospasm was based on exclusion of other causes of delayed neurological deficit such as rebleeding, hydrocephalus, electrolyte disturbance, and seizure. 1,5,7,8 Overall outcome was assessed 3 months following SAH using the Glasgow Outcome Scale. 1 Transient vasospasm indicated complete recovery of DIND within 3 months.

Statistical values are expressed as mean ± SD, and were compared with the unpaired t-test. Comparison of background characteristics, incidence of vasospasm, and clinical outcome between the two groups used the chi-square test. A significant statistical difference was defined as p < 0.05.

### Results

Administration of FUT-175 significantly decreased the overall incidence of symptomatic vasospasm including permanent and transient vasospasm (p < 0.001, Table 2). Administration of FUT-175 significantly decreased the incidence of symptomatic vasospasm in patients with Hunt and Hess grade 3 (p < 0.02) and grade 4 (p < 0.02). The incidence of symptomatic vasospasm in patients with grade 1 plus 2 was also decreased but no statistical difference was found.

Patients who had received FUT-175 tended to achieve a more favorable outcome (good recovery or moderate disability), but this difference was not

<table>
<thead>
<tr>
<th>Table 1 Characteristics of patients</th>
<th>FUT group</th>
<th>Non-FUT group</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>34</td>
<td>455</td>
</tr>
<tr>
<td>female</td>
<td>24 (70.6)</td>
<td>293 (64.4)</td>
</tr>
<tr>
<td>Mean age (yrs)</td>
<td>69.6 ± 13.4</td>
<td>60.5 ± 11.7</td>
</tr>
<tr>
<td>Hunt and Hess grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>1 (2.9)</td>
<td>18 (4.0)</td>
</tr>
<tr>
<td>II</td>
<td>6 (17.6)</td>
<td>134 (29.5)</td>
</tr>
<tr>
<td>III</td>
<td>16 (47.1)</td>
<td>204 (44.8)</td>
</tr>
<tr>
<td>IV</td>
<td>9 (26.5)</td>
<td>86 (18.9)</td>
</tr>
<tr>
<td>V</td>
<td>2 (5.9)</td>
<td>13 (2.9)</td>
</tr>
<tr>
<td>Location of aneurysm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACoA</td>
<td>9 (26.5)</td>
<td>161 (35.4)</td>
</tr>
<tr>
<td>ICA</td>
<td>14 (41.2)</td>
<td>134 (29.5)</td>
</tr>
<tr>
<td>MCA</td>
<td>1 (2.9)</td>
<td>28 (6.2)</td>
</tr>
<tr>
<td>ACA</td>
<td>0</td>
<td>6 (1.3)</td>
</tr>
<tr>
<td>others</td>
<td>0</td>
<td>7 (1.5)</td>
</tr>
<tr>
<td>Aneurysm clipping</td>
<td></td>
<td></td>
</tr>
<tr>
<td>day 0</td>
<td>11 (32.4)</td>
<td>150 (33.0)</td>
</tr>
<tr>
<td>day 1</td>
<td>20 (58.8)</td>
<td>209 (45.9)</td>
</tr>
<tr>
<td>day 2</td>
<td>2 (5.9)</td>
<td>63 (13.8)</td>
</tr>
<tr>
<td>day 3</td>
<td>1 (2.9)</td>
<td>33 (7.3)</td>
</tr>
</tbody>
</table>

Values in parentheses indicate percentages. Statistical values are expressed as mean ± SD. A: anterior cerebral artery, ACoA: anterior communicating artery, BA: basilar artery, day 0: day of subarachnoid hemorrhage, ICA: internal carotid artery, MCA: middle cerebral artery.
However, if patients with grade 5 who suffered from serious neurological deficit caused by the direct effect of SAH were excluded, 26 of 32 patients in the FUT group (81.3%) showed favorable outcome, which was significantly higher than the 62.0% in the non-FUT group (p < 0.05).

Two patients were given less than 80 mg/day of FUT-175 in the initial study, but both developed symptomatic vasospasm (Fig. 1). FUT-175 was initiated on day 2 of SAH in one patient and on day 3 of SAH in another. In the subsequent study, a dose of 80 mg/day or higher was used. The incidence of symptomatic vasospasm decreased from 29.4% to 25% in the FUT group after exclusion of these two patients. Only three of 13 patients treated with 80 mg/day FUT-175 exhibited symptomatic vasospasm, whereas five of 19 patients who received more than 80 mg/day of FUT-175 developed symptomatic vasospasm. This difference was not significant. The significance of the timing of FUT therapy was also evaluated in patients treated with 80 mg/day or more (Fig. 2). When FUT therapy was started within day 2 of SAH, the incidence of symptomatic vasospasm was 16.7%, but increased to 50% by late initiation of FUT therapy (start at day 3 or 4 after SAH). However, no statistical difference was demonstrated between these two groups.
Discussion

This preliminary study of the preventive effects of FUT-175 examined patients with thick SAH on CT who were at greater risk to develop vasospasm. Our results suggest that administration of FUT-175 in addition to OKY-046 significantly decreases the incidence of symptomatic vasospasm in these high risk patients. Our results show that a dose of 80 mg/day beginning on day 1 or 2 after SAH will achieve the optimum effect. Study of 304 patients with ruptured cerebral aneurysms in the anterior circulation treated surgically within 72 hours found that the incidence of symptomatic vasospasm was significantly different between patients with Hunt and Kosnik grades 2 and 3.7) In our study in non-FUT patients with thick SAH, symptomatic vasospasm also developed more frequently in Hunt and Hess grade 3 group than the grade 1 plus 2 group (p < 0.001). FUT-175 significantly reduced the incidence of vasospasm in these higher neurological grades (Table 2). Severe brain injury is primarily caused by SAH in patients with grade 5, and our present study revealed the poor outcome for such patients in both the FUT and the non-FUT groups. Evaluation of the patients with Hunt and Hess grades 1–4 showed FUT-175 improved the outcome significantly (p < 0.05).

The therapeutic benefit of FUT-175 may be due both to preventing or ameliorating vasospasm and also to protecting neuronal elements against vasospasm-induced ischemia. Vasospasm usually develops between days 4 and 14 after SAH. The half-life of FUT-175 is short,12) and FUT-175 treatment is initiated between days 1 and 2 after SAH and is used for only 4 days. Thus, the effect of FUT-175 probably does not continue till the late phase of vasospasm. Furthermore, the present study suggests that early initiation of FUT therapy is more effective to prevent symptomatic vasospasm. Therefore, FUT-175 is unlikely to reduce the incidence of DIND through neuronal protection or improvement of microcirculation in the ischemic area. Although we did not verify the effect of FUT-175 angiographically, we suggest that FUT-175 prevents symptomatic vasospasm through initiation of the complement cascade during the acute stage of SAH.

These beneficial effect of FUT-175 appears to be additive to that of the thromboxane synthetase inhibitor, OKY-046.20) We and our affiliated hospitals have been using OKY-046, which is a potent agent to prevent vasospasm between 1989 and 1994 as standard care to prevent or reduce DIND due to vasospasm. Clinical data from the 1905 patients treated were deposited in the Nagasaki SAH Data Bank. Imbalance in the synthesis of TXA2 and prostacyclin results in vasoconstriction and platelet aggregation, in which intimal changes are involved.16) Since intimal changes occur in the early stage of vasospasm,19) this imbalance probably occurs after the initiation of vasospasm. Therefore, TXA2 synthetase inhibitors may act to block the progression of vasospasm rather than prevent the initiation of vasospasm. This hypothesis is supported by the observation that enhancement of platelet function appears after day 5 in SAH patients with symptomatic vasospasm.21) Since we have no data on the outcome of patients with SAH not treated by OKY-046, we did not evaluate the effect of only FUT-175 treatment. However, this study suggests that the combined use of FUT-175, which may prevent the initiation of vasospasm, and OKY-046, which may act to inhibit progression of vasospasm, has an additive effect for the prevention of symptomatic vasospasm in high risk patients.

Hemorrhagic complications may be associated with OKY-046.21) However, present study found no such complication in either the FUT or the non-FUT group, except one patient in the non-FUT group who died from acute subdural hematoma of unknown cause on day 12 of SAH. No other serious adverse effect of FUT-175 was experienced.

The combination of serine protease inhibitor FUT-175 and TXA2 synthetase inhibitor OKY-046 can reduce the incidence of symptomatic vasospasm and improve the clinical outcome in patients with thick SAH on CT.

References

5) Gurusinghe NT, Richardson AE: The value of computerized tomography in aneurysmal subarachnoid hemorrhage. The concept of the CT score. J Neu-
14) Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves
13) Jennett B, Bond M: Assessment of outcome after se
12) Ikari N, Sakai Y, Fujii S: New synthetic inhibitor to
11) Hunt WE, Hess RM: Surgical risk as related to time of
10) Hughes JT, Schianchi PM: Cerebral artery spasm: A

6) Haley EC Jr, Kassell NF, Torner JC, the participants:
5) Ohkuma H, Suzuki S, Kimura M, Sobata E: Role of
4) Pellettieri I, Nilsson B, Carlsson CA, Nilsson U: Serum
3) Selfert V, Stolke D, Reale E: Ultrastructural changes of
2) Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T,
1) Hunt WE, Hess RM: Surgical risk as related to time of

19) Seifert V, Stolke D, Reale E: Ultrastructural changes of
18) Pellettieri I, Nilsson B, Carlsson CA, Nilsson U: Serum
17) Ohkuma H, Suzuki S, Kimura M, Sobata E: Role of
16) Moncada S, Vane JR: Arachidonic acid metabolites
15) Kasuya H, Shimizu T: Activated complement compo
14) Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves
13) Jennett B, Bond M: Assessment of outcome after se
12) Ikari N, Sakai Y, Fujii S: New synthetic inhibitor to
11) Hunt WE, Hess RM: Surgical risk as related to time of
10) Hughes JT, Schianchi PM: Cerebral artery spasm: A

Address reprint requests to: M. Kaminogo, M.D., Department of Neurosurgery, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

Commentary

This paper discusses the interesting part possibly played by inflammatory factors in the development of delayed vasospasm, presenting both histological and biochemical evidence in support. The use of FUT-175, an inhibitor of the complement system, has arisen from this. The results presented do go some way towards supporting this hypothesis, with a reduced incidence of symptomatic vasospasm in the group receiving FUT-175 as well as OKY-046, and an improved three-month outcome in this group for grade 1–4 patients.

However, I don't think one can be more definite than that at present, since this was not a randomized study, but the FUT-175 patients were compared with controls from presumably a number of centers in the district (concurrent or historical?). Also, even though the controls were also Fisher grade 3, the incidence of delayed spasm of more than 57% seems rather high. Confirmation of spasm by transcranial Doppler or an-
The authors studied the preventive effects of serine protease inhibitor, FUT-175, combined with OKY-046 for the prevention of symptomatic cerebral vasospasm. The study showed that the administration of FUT-175 with OKY-046 significantly decreased the incidence of symptomatic cerebral vasospasm and obtained a more favorable outcome compared with administration of OKY-046 alone.

There may be possible differences between two groups, FUT group and non-FUT group, in terms of surgical techniques, nutritional status, administration of other drugs like a Ca++ antagonists and so on, because the background of each group is quite different. Comparison of clinical data between two groups is, therefore, not always proper. Other preventive measures used should also be taken into consideration in a comparative study of this sort.

The occurrence rate of symptomatic vasospasm in the non-FUT group (57%) seems to correspond to that found in the natural course of subarachnoid hemorrhage, therefore, the superior clinical result in the FUT group may be caused simply by the effect of FUT. We would like to know whether there is any synergistic effect between two drugs. The preventive mechanisms of FUT-175, which is probably based on its anti-inflammatory effect, should also be investigated by clinical laboratory methods prior to and following treatment to analyze such factors as inflammatory products or reactions in the cerebrospinal fluid.

Shigeharu SUZUKI, M.D.
Department of Neurosurgery
Hirosaki University School of Medicine
Aomori, Japan